Bioaffinity Technologies Warrant Stock Today
| BIAFW Stock | USD 0.27 0.00 0.00% |
PerformanceInsignificant
| Odds Of DistressHigh
|
BioAffinity Technologies is selling for under 0.27 as of the 26th of March 2025; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.27. BioAffinity Technologies has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 26th of December 2024 and ending today, the 26th of March 2025. Click here to learn more.
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. More on bioAffinity Technologies Warrant
Moving against BioAffinity Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
BioAffinity Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) |
| Financial Strength | |
bioAffinity Technologies Warrant (BIAFW) is traded on NASDAQ Exchange in USA. It is located in 22211 West Interstate 10, San Antonio, TX, United States, 78257 and employs 75 people. BioAffinity Technologies is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08.
Check BioAffinity Technologies Probability Of Bankruptcy
BioAffinity Technologies Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. BioAffinity Technologies market risk premium is the additional return an investor will receive from holding BioAffinity Technologies long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0481 | |||
| Jensen Alpha | 0.8739 | |||
| Total Risk Alpha | 0.9338 | |||
| Sortino Ratio | 0.0733 |
BioAffinity Stock Against Markets
BioAffinity Technologies Corporate Management
| Timothy JD | Secretary VP | Profile | |
| Dallas Coleman | National Sales | Profile | |
| William Bauta | Senior Therapeutics | Profile | |
| Maria JD | President, Founder | Profile | |
| Xavier MS | VP Operations | Profile |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.